Menu
Recruiting NCT06203249

Microecology and Immunity in Patients With Anti-MDA5 Antibody Positive Dermatomyositis and Interstitial Lung Disease

Observational Microbiome Immune Function Anti-MDA5 Antibody Positive Dermatomyositis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Microbiome, Immune Function, Anti-MDA5 Antibody Positive Dermatomyositis. Basic parameters: 18 years — 100 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Microecology and Host Immunity in Patients With Anti-melanoma Differentiation Associated Gene 5 Antibody Positive Dermatomyositis and Interstitial Lung Disease

Overview

The purpose of this study was to analyze the relationship between the microbial community, host immunity and the presence or absence of concurrent rapidly progressive interstitial lung disease patients with anti-MDA5 antibody positive dermatomyositis.

Detailed description

Methods: Bronchoalveolar lavage specimens of patients with anti-MDA5 antibody positive dermatomyositis and interstitial lung disease were collected and studied to analyze the relationship between the composition of patients' microecology and the occurrence and development of disease.

Primary outcome measures

  • The relationship between the microbial community and the presence or absence of interstitial lung disease [Time frame: 6 months]

Eligibility criteria

Inclusion criteria

  • Patients who meet the diagnostic criteria of dermatomyositis and anti-MDA 5 antibody positive.
  • Anti-MDA5 antibody positive DM patients with RPILD meet the diagnostic criteria for RPILD.
  • Must have undergone bronchoalveolar lavage.
  • Age≥18 years old.
  • Patients who signed informed consent forms

Exclusion criteria

  • Patients who had other connective tissue diseases.
  • Patients with ILD or RPILD caused by infection, tumors, drugs, biochemistry and other factors.
  • Pregnant or lactating patients.
  • The patient also participated in any other clinical trial.
  • Disagreement for inclusion in this study

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

China · 1 center
  • PLA — Beijing

Identifiers

NCT: NCT06203249 · Microecology and Immunity 1

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗